CytomX: Initiation of Phase 1 expansion cohort for Varseta-M planned for 2H26

CytomX announced pipeline program updates: Announced positive data update from Phase 1 dose expansion study of Varseta-M in patients with advanced colorectal cancer. The company aims to align with the FDA in 2026 on a potential registrational study design for Varseta-M monotherapy in advanced CRC. Additional Phase 1 follow-up data are also expected to be presented at major medical meeting(s) in 2026. A Phase 1 Varseta-M combination study with bevacizumab in CRC has been initiated and a Phase 1b/2 study in combination with bevacizumab and chemotherapy is expected to start by the end of 2026. Initiation of Phase 1 expansion cohort(s) in additional indications is planned for 2H 2026.